Target intelligence / Profile preview

Phosphoinositide 3-kinase alpha-RAS protein-protein interface (PI3Kα-RAS PPI) (PI3Kα-RAS PPI)

Target
PI3Kα-RAS PPI
Molecular classification
Protein-protein interface, Enzyme-GTPase complex, Intracellular signaling complex
01

Overview

The Phosphoinositide 3-kinase alpha (PI3Kα)-RAS protein-protein interface is a critical signaling node where the small GTPase RAS interacts with the Ras-binding domain (RBD) of the p110α catalytic subunit of PI3K (Gupta et al., 2007, Cell). This interaction is essential for the recruitment of PI3K to the plasma membrane and its subsequent activation, which triggers the AKT/mTOR signaling pathway to promote cell growth, survival, and metabolism (Rodriguez-Viciana et al., 1994, Nature). In many cancers, particularly those driven by KRAS mutations such as lung, colorectal, and pancreatic cancers, this interface is constitutively active or hyper-responsive, making it a high-priority therapeutic target (Fritsch et al., 2013, Cancer Discovery). Unlike traditional PI3K inhibitors that target the ATP-binding pocket of the kinase, inhibitors of the PI3Kα-RAS interface aim to specifically decouple PI3K signaling from oncogenic RAS. This approach potentially offers a more selective therapeutic window by sparing the basal, RAS-independent functions of PI3K in normal cells. Research into small molecules like rigosertib and peptidomimetics that disrupt this interface is ongoing, with the goal of overcoming resistance mechanisms associated with direct RAS or PI3K kinase inhibition (Athuluri-Divakar et al., 2016, Cell).

Other names
p110α-RAS interfacePI3K-RAS interactionRAS-binding domain of p110αPIK3CA-RAS interface
02

Mechanism of action

Disruption of the physical interaction between the RAS-binding domain (RBD) of the p110α subunit of PI3K and active RAS-GTP, thereby preventing RAS-mediated recruitment and activation of PI3K at the plasma membrane.

03

Biological functions

Signal transductionCell proliferationCell survivalMetabolic regulationVascular development
04

Disease associations

CancerNon-small cell lung cancerColorectal cancerPancreatic ductal adenocarcinomaPIK3CA-related overgrowth syndrome (PROS)
05

Safety considerations

HyperglycemiaGastrointestinal toxicityPotential disruption of normal RAS-effector signaling in healthy tissuesFeedback activation of compensatory pathways (e.g., MAPK)
06

Interacting drugs

Rigosertib (ON 01910.Na)
07

Biomarkers

KRAS mutation statusPIK3CA mutation statusPhospho-AKT (p-AKT) levelsPhospho-S6 (p-S6) levels

Beyond the preview

Go deeper on Phosphoinositide 3-kinase alpha-RAS protein-protein interface (PI3Kα-RAS PPI) (PI3Kα-RAS PPI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphoinositide 3-kinase alpha-RAS protein-protein interface (PI3Kα-RAS PPI) (PI3Kα-RAS PPI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call